Biotech Values

[oc631]

On the other hand, GILD seems to have GT2 well covered already.

[GT2] It may be a challenge for GILD to replace generic ribavirin with a DAA in an attempt to boost the tolerability of the existing SOC. Adding riba lead to dramatic increase in SVR rates over sofosbuvir monotherapy. Ribavirin has high antiviral activity in GT2 patients (specifically) and perhaps the reason GT2's are labeled the "easiest to treat" with oral therapy.